Axsome Therapeutics

Axsome Therapeutics

Yahoo Finance • 3 days ago

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

Axsome Therapeutics (NASDAQ: AXSM), a biotech company, has performed fairly well this year. The company's shares are up 16% versus the S&P 500's 11%. Could the stock rise even higher? Wall Street certainly thinks so. Axsome Therapeutics' a... Full story

Yahoo Finance • 17 days ago

Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA

Earnings Call Insights: Axsome Therapeutics (AXSM) Q2 2026 MANAGEMENT VIEW * "The second quarter was highly productive for Axsome as we grew our commercial business robustly and made important regulatory and clinical progress across ou... Full story

Yahoo Finance • 17 days ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Barrick Mining Corporation (B [https://seekingalpha.com/symbol/B]) * Medical Properties Trust (MPT [https://seekingalpha.com/symbol/MPT]) * Seadrill Limited (SDRL [https:/... Full story

Yahoo Finance • 21 days ago

The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight

The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovis bio), Masitinib (AB Science), Remtern... Full story

Yahoo Finance • last month

Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug

ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its "Small Cap Growth Strategy". A copy of the letter can be downloaded here. The Russell 2000 Growth Index increased by 25.6% in the s... Full story

Yahoo Finance • 2 months ago

William Blair updates conviction list: Oracle in, Meta out and more

[Technology background image, graph, displaying analytical data about stock trading.] Donny DBM William Blair added Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), American Express (AXP [https://seekingalpha.com/symbol/AXP]), Ecolab... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Axsome Therapeutics, Inc. NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today annou... Full story

Yahoo Finance • 4 months ago

3 Overlooked Stocks Set to Soar in 2026

Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors. Axsome Therapeutics(NASDAQ: AXSM) is a mid-cap with only three approved therapies, while sma... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: Berkshire, AMD, Circle, FedEx, UPS & more

Check out the companies making the biggest moves in midday trading. Logistics firms — Shares of logistics companies were under pressure after Amazon said it would launch Amazon Supply Chain Services , its own freight, distribution, fulfill... Full story

Yahoo Finance • 4 months ago

Axsome (AXSM) Q2 2025 Earnings Transcript

Image source: The Motley Fool. DATE Monday, Aug. 4, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Herriot Tabuteau Chief Financial Officer — Nick Pizzie Chief Commercial Officer — Ari Maizel Chief Operating Officer — Ma... Full story

Yahoo Finance • 4 months ago

Axsome (AXSM) Q1 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Monday, May 5, 2025 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Herriot Tabuteau Chief Financial Officer — Nick Pizzie Chief Commercial Officer — Ari Maizel Chief Operating Office... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves premarket: eBay, Norwegian Cruise Line, Coinbase & more

Check out the companies making the biggest moves premarket: eBay — Shares of the online marketplace jumped nearly 9% after GameStop made an unsolicited, non-binding offer Sunday to buy eBay for roughly $55.5 billion. GameStop CEO Ryan Cohe... Full story

Yahoo Finance • 4 months ago

Why Axsome Therapeutics Stock Jumped Over 20% in April

Axsome Therapeutics(NASDAQ: AXSM) has been growing sales rapidly with its Auvelity antidepressant. The biopharmaceutical company focuses on developing therapies for central nervous system (CNS) disorders. Auvelity, launched in late 2022,... Full story

Yahoo Finance • 4 months ago

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and confere... Full story

Yahoo Finance • 4 months ago

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of AUVELITY in agitation associated with... Full story

Yahoo Finance • 4 months ago

Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether Axsome Therapeutics at around US$178... Full story

Yahoo Finance • 5 months ago

Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Axsome Therapeutics (NasdaqGM:AXSM) is awaiting an FDA decision this month on Auvelity for agitation associated with Alzhei... Full story

Yahoo Finance • 5 months ago

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

Axsome Therapeutics (AXSM) could see meaningful upside ahead of a US Food and Drug Administration de PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story

Yahoo Finance • 5 months ago

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome Therapeutics, Inc. Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a novel mecha... Full story